Bioscience Equity Partners is proud to share an exclusive in-depth interview with our Founder and CEO Dr. George Syrmalis, exploring the scientific and strategic philosophy behind BEP’s global biotech investment model.
In this interview he reflects on the turning points that led to the creation of BEP, the firm’s differentiated approach to scientific diligence and institutional capital allocation, and what is required for early stage biotech companies to progress from laboratory innovation to a successful public listing. Dr. Syrmalis also shares his perspective on the technologies that will define the coming decade, including radiopharmaceuticals, precision immunotherapy, AI enabled drug design, next generation diagnostics, and advanced biomanufacturing, and how BEP is positioned to guide these innovations from concept to real patient impact.
With a career spanning clinical medicine, nuclear imaging, radiation immunology, and venture creation across multiple continents, Dr. Syrmalis discusses the core insight that shaped his path: great science often fails not because the science is weak, but because the capital structures supporting it are not built to manage scientific and regulatory complexity.
For the complete conversation with Dr. George Syrmalis, explore the full interview:
